Skip to main content
SyntekaBio,Inc. logo

SyntekaBio,Inc. — Investor Relations & Filings

Ticker · 226330 ISIN · KR7226330009 KO Professional, scientific and technical activities
Open in API
Filings indexed 322 across all filing types
Latest filing 2025-01-03 Proxy Solicitation & In…
Country KR South Korea
Listing KO 226330

About SyntekaBio,Inc.

https://www.syntekabio.com/

SyntekaBio is an AI-driven drug discovery company that utilizes its proprietary supercomputing infrastructure, the AI Bio-Supercom Center, to accelerate pharmaceutical development. The company's core technology, the DeepMatcher® platform, underpins a suite of services for discovering small molecules, antibodies, and neoantigens for personalized cancer vaccines. A key offering is LaunchPad, a factory-like system that continuously generates a stream of 'off-the-shelf' drug candidates for numerous disease targets, aiming to expedite the path to IND-enabling studies. SyntekaBio delivers its solutions through comprehensive discovery partnerships and a modular, cloud-based Software as a Service (SaaS) platform, STB CLOUD, providing researchers with automated tools for drug development and genomics analysis.

Recent filings

Filing Released Lang Actions
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy/Voting Rights) and is a formal filing submitted to the Financial Supervisory Service (FSS) in South Korea. It details the agenda for an upcoming Extraordinary General Meeting (EGM), including proposed changes to the articles of incorporation and the approval of stock options. This document is a standard proxy solicitation statement used to request shareholder votes, which falls under the 'Proxy Solicitation & Information Statement' category.
2025-01-03 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a formal 'Notice of Extraordinary General Meeting of Shareholders' (임시주주총회 소집공고) issued by Syntekabio. It contains the meeting agenda, date, location, and instructions for electronic voting. While it includes management information and business descriptions, these are provided as 'Management Reference Materials' (경영참고사항) required by law to be attached to the meeting notice. Since the primary purpose of the document is to solicit shareholder attendance and provide information for the upcoming meeting, it is classified as a Proxy Solicitation & Information Statement.
2024-12-30 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used by companies to solicit proxies from shareholders for an upcoming general meeting. It contains details about the meeting date, the purpose of the meeting (such as amendments to the articles of incorporation), and instructions for electronic voting. This fits the definition of a Proxy Solicitation & Information Statement (PSI).
2024-12-30 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결) between Syntekabio and LudaCure. It details the contract value, duration, and terms. Since this is a specific regulatory announcement of a business contract that does not fit into the other specialized categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2024-12-19 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date and shareholder register closure for an upcoming Annual General Meeting (AGM). It does not contain the full AGM materials or voting results, but rather serves as a formal regulatory notice of the procedural steps for the meeting. Given it is a standard regulatory announcement that does not fit into specific categories like 'AGM-R' (which implies presentation materials) or 'DVA' (which implies results), it falls under the general regulatory filing category.
2024-12-13 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date and shareholder register closure for an upcoming Extraordinary General Meeting (EGM). It does not contain the full proxy materials or the meeting results themselves, but rather serves as a formal regulatory notice of the procedural steps for the meeting. Given it is a standard regulatory announcement regarding corporate governance procedures, it fits best under the general regulatory filings category.
2024-12-05 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.